Skip to main content

Advertisement

Table 4 CTL response to CDCA1, CDH3 and KIF20A

From: Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Peptide dose No. Course CTL response
CDCA1 CDH3 KIF20A Positive control
1 mg 1 Pre - + - +++
Post 1 - - + +++
Post 2 - - - +++
2 Pre - - - +++
Post 1 ++ - + +++
3 Pre + - - +++
Post 1 NA* NA NA +++
Post 2 - + - +++
Post 3 + ++ - +++
Post 4 + - + +++
2 mg 4 Pre + - + +++
Post 1 - - + +++
Post 2 + - + +++
Post 3 - - - +++
5 Pre - - - +++
Post 1 - - - +++
Post 2 - - + +++
Post 3 + - +++ +++
Post 4 - - ++ +++
Post 5 + + - +++
Post 6 - - - +++
6 Pre - + - +++
Post 1 + + - +++
Post 2 + + - +++
3 mg 7 Pre NA NA NA +++
Post 1 - - - +++
Post 2 ++ + ++ +++
8 Pre - - + +++
Post 1 - + - +++
Post 2 ++ + ++ +++
Post 3 +++ +++ + +++
Post 5 +++ +++ +++ +++
9 Pre + - + +++
Post 1 ++ + + +++
Post 2 - + - +++
Post 3 - +++ + +++
Post 4 ++ - - +++
Post 6 ++ + ++ +++
  1. *NA: not analyzed.